Bidding for Pliva

Pliva d.d. shares soared to the highest level in more than eight years after the Financial Times said Barr Pharmaceuticals Inc. may have offered $2.1 billion for eastern Europe's largest drugmaker.
...
Pliva Chief Executive Officer Zeljko Covic is in talks with several companies and has said he will present investors with a list of potential buyers in coming months. He started talking to other pharmaceutical companies after receiving an unsolicited bid from Icelandic generic-drug maker Actavis hf in March.
...
Generic versions of biologically engineered drugs, which are altered forms of proteins and other naturally occurring substances from the human body, loom as a potentially key profit driver for generic drug companies.
...
European regulators are seen as moving faster than their U.S. counterparts in paving the way to develop generic versions of such biologic medicines, which generally are more complicated to duplicate than traditional, chemically derived pharmaceuticals.

1 2 3